AR103415A1 - Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 - Google Patents
Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2Info
- Publication number
- AR103415A1 AR103415A1 ARP160100087A ARP160100087A AR103415A1 AR 103415 A1 AR103415 A1 AR 103415A1 AR P160100087 A ARP160100087 A AR P160100087A AR P160100087 A ARP160100087 A AR P160100087A AR 103415 A1 AR103415 A1 AR 103415A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- type
- pediatric patients
- mellitus diabetes
- lixisenatide
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 abstract 3
- 229960001093 lixisenatide Drugs 0.000 abstract 3
- 108010004367 lixisenatide Proteins 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000011374 additional therapy Methods 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15151488 | 2015-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103415A1 true AR103415A1 (es) | 2017-05-10 |
Family
ID=52354814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100087A AR103415A1 (es) | 2015-01-16 | 2016-01-14 | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160235818A1 (enExample) |
| EP (1) | EP3244912B1 (enExample) |
| JP (1) | JP7274258B2 (enExample) |
| KR (1) | KR102614574B1 (enExample) |
| CN (1) | CN107405386A (enExample) |
| AR (1) | AR103415A1 (enExample) |
| AU (1) | AU2016207964B2 (enExample) |
| CL (1) | CL2017001843A1 (enExample) |
| CR (1) | CR20170376A (enExample) |
| EA (1) | EA035423B1 (enExample) |
| ES (1) | ES2895513T3 (enExample) |
| IL (1) | IL253460B (enExample) |
| MX (1) | MX381944B (enExample) |
| PH (1) | PH12017501290A1 (enExample) |
| PL (1) | PL3244912T3 (enExample) |
| PT (1) | PT3244912T (enExample) |
| SG (1) | SG11201705755UA (enExample) |
| TN (1) | TN2017000292A1 (enExample) |
| TW (1) | TWI706779B (enExample) |
| WO (1) | WO2016113404A1 (enExample) |
| ZA (1) | ZA201704512B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| MA41138B1 (fr) | 2014-12-12 | 2023-07-31 | Sanofi Aventis Deutschland | Formulation à rapport fixe d'insuline glargine/lixisenatide |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| DE102019129444A1 (de) * | 2019-10-31 | 2021-05-06 | Lts Lohmann Therapie-Systeme Ag | Lagtime-Verkürzung/Eisspray |
| US20240201166A1 (en) * | 2021-04-11 | 2024-06-20 | Vikas Khurana | Diagnosis and treatment of congestive colon failure (ccf) |
| WO2024133412A1 (en) | 2022-12-21 | 2024-06-27 | Novo Nordisk A/S | Methods and systems for estimating fbg value from cgm data |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| TWI466672B (zh) | 2009-01-29 | 2015-01-01 | Boehringer Ingelheim Int | 小兒科病人糖尿病之治療 |
| WO2010138671A1 (en) * | 2009-05-28 | 2010-12-02 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
| EP2324853B1 (en) * | 2009-11-13 | 2015-08-26 | Sanofi-Aventis Deutschland GmbH | Lixisenatide as add-on to metformin in the treatment of diabetes type 2 |
| ES2556466T3 (es) * | 2011-05-13 | 2016-01-18 | Sanofi-Aventis Deutschland Gmbh | Lixisenatida y metformina para el tratamiento de la diabetes tipo 2 |
| US9821032B2 (en) * | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| US20130090285A1 (en) * | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| WO2013030160A1 (en) * | 2011-08-29 | 2013-03-07 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| CA2851690C (en) * | 2011-10-28 | 2022-07-26 | Sanofi-Aventis Deutschland Gmbh | Treatment protocol of diabetes type 2 |
-
2016
- 2016-01-14 AR ARP160100087A patent/AR103415A1/es unknown
- 2016-01-14 US US14/995,910 patent/US20160235818A1/en not_active Abandoned
- 2016-01-14 TW TW105101028A patent/TWI706779B/zh active
- 2016-01-15 PL PL16700758T patent/PL3244912T3/pl unknown
- 2016-01-15 CN CN201680016033.2A patent/CN107405386A/zh active Pending
- 2016-01-15 KR KR1020177022646A patent/KR102614574B1/ko active Active
- 2016-01-15 WO PCT/EP2016/050804 patent/WO2016113404A1/en not_active Ceased
- 2016-01-15 EP EP16700758.2A patent/EP3244912B1/en active Active
- 2016-01-15 ES ES16700758T patent/ES2895513T3/es active Active
- 2016-01-15 MX MX2017009294A patent/MX381944B/es unknown
- 2016-01-15 SG SG11201705755UA patent/SG11201705755UA/en unknown
- 2016-01-15 EA EA201791611A patent/EA035423B1/ru not_active IP Right Cessation
- 2016-01-15 CR CR20170376A patent/CR20170376A/es unknown
- 2016-01-15 PT PT16700758T patent/PT3244912T/pt unknown
- 2016-01-15 AU AU2016207964A patent/AU2016207964B2/en active Active
- 2016-01-15 JP JP2017537500A patent/JP7274258B2/ja active Active
- 2016-01-15 TN TNP/2017/000292A patent/TN2017000292A1/en unknown
-
2017
- 2017-07-04 ZA ZA2017/04512A patent/ZA201704512B/en unknown
- 2017-07-13 IL IL253460A patent/IL253460B/en unknown
- 2017-07-14 PH PH12017501290A patent/PH12017501290A1/en unknown
- 2017-07-14 CL CL2017001843A patent/CL2017001843A1/es unknown
-
2019
- 2019-02-04 US US16/266,873 patent/US20190365864A1/en not_active Abandoned
-
2020
- 2020-09-22 US US17/028,400 patent/US20210187075A1/en not_active Abandoned
-
2023
- 2023-08-07 US US18/366,130 patent/US20240173384A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| CL2015002941A1 (es) | Usos terapéuticos de empaglifozina | |
| CL2015002940A1 (es) | Usos terapéuticos de empaglifozina. | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CO2018009561A2 (es) | Métodos para tratar la depresión con antagonistas del receptor de orexina-2 | |
| UY34918A (es) | Nuevos ácidos 5-aminotetrahidroquinolin-2-carboxílicos y su uso | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CL2012003197A1 (es) | Formulación farmacéutica acuosa que comprende 200-1000 u/ml de insulina glargina, con condición de que la concentración de dicha formulación no sea 684 u/ml de insulina glargina; y su uso para tratar diabetes mellitus de tipo i y tipo ii en un paciente. | |
| BR112013029256A2 (pt) | "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina". | |
| BR112016018548A2 (pt) | composto, ácido, medicamento, e, uso de um composto. | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| MX389091B (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2. | |
| CL2016000026A1 (es) | Nuevos derivados de azabencimidazol | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| MX2015014007A (es) | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada. | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| CR20170470A (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| AR085998A1 (es) | Aclidinio y su uso en la mejora de la calidad del sueño | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| AR094063A1 (es) | Uso de aclidinio, composicion farmaceutica y metodo para mejorar la actividad fisica en pacientes respiratorios | |
| AR103944A1 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| CL2014003072A1 (es) | Uso de un compuesto 2-((2r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida (veliparib o abt-888) o de una sal farmaceuticamente aceptable que sirve para el tratamiento de las metástasis en el cerebro con una combinación de una terapia con radiación en la totalidad del cerebro. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |